Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of erlotinib + pemetrexed versus erlotinib or pemetrexed alone in second-line nonsmoking patients with advanced nonsquamous non-small cell lung cancer
2007-003912-72Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Erlotinib + pemetrexed, Erlotinib alone and Pemetrexed alone (3 arms). Primary endpoint: Progression-free survival. Started Aug 2007; status: completed.
02
Drugs
erlotinibpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-003912-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003912-72.